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Abstract
Objective Seasonal vaccination has been consistently shown to
significantly reduce morbidity and mortality because of influenza
epidemics, even in healthy, working adults. Here we report the
results of the yearly licensing studies of the past 11 influenza
seasons (1997–2007) with a trivalent, inactivated whole virus
vaccine with an aluminum phosphate adjuvant system.
Methods Sixty healthy volunteers per age group (18–60 years and
60 years and older) were enrolled to receive vaccination each year,
thus, a total of 1080 subjects were studied. Serum antibody titers
were measured by hemagglutination inhibition (HI).
Results: The vaccine met the criteria for licensing each year,
meaning seroprotection (achievement of an HI titer of >1:40 in
>70% of subjects); seroconversion, i.e. a >4-fold increase in HI
antibody titer, or reaching a titer of >1:40, in >40% of
subjects; and an increase in geometric mean titers by
>2Æ5-fold. Side effects were rare and mild. The same method
was used to produce a pre-pandemic vaccine against influenza
A (H5N1), which has been shown to be safe and immunogenic
in humans.
Conclusions We conclude that the method presented is safe,
effective and may serve as a useful approach to seasonal and
pandemic vaccine production even in less well-developed
countries by means of technological transfer.
Keywords Influenza, licensing, seasonal, vaccine.
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Introduction
Influenza is among the leading causes of respiratory infec-
tion and it represents a significant public health burden.
Elderly people and patients with underlying health condi-
tions are at increased risk of complications of influenza,
including hospitalization and death.1 During epidemics, the
hospitalization rate for the elderly and people with chronic
health problems may increase two to fivefold compared
with non-epidemic periods.1 Seasonal vaccination has been
consistently shown to significantly reduce morbidity and
mortality because of influenza epidemics, even in healthy,
working adults.2
It has been suggested that an influenza pandemic can
occur in the near future, and that an influenza A (H5N1)
virus might be the cause of the next pandemic.3 However,
pandemic vaccine development has progressed slowly.
Experts suggest that validated methods for seasonal (inter-
pandemic) vaccine production could be useful and easier
to be utilized for pandemic vaccines, as facilities are already
available for production.4,5
Influenza vaccine development and production has a
half-century long history in Hungary. Between 1961 and
1995 the vaccine against seasonal influenza was produced
at the Hungarian National Institute of Public Health.
The production technology has continuously been
improved, but the basic idea of the method remained
unchanged. The vaccine contains whole, inactivated virus,
with an adjuvant system. In 1995, Omninvest Ltd (Buda-
pest, Hungary) received a national marketing authoriza-
tion for influenza vaccine, by using essentially the same
method.
DOI:10.1111/j.1750-2659.2008.00055.x
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Here we report the 11-year experience with a seasonal,
inactivated whole virus vaccine with an aluminum phos-
phate adjuvant system. The unique parts of the method are
the concentration and purification of the virus and the
adjuvant system. The same method was used to produce a
pandemic mock up vaccine against H5N1, which has been
shown to be safe and immunogenic in humans after just
one dose.6
Methods
Vaccine
We report the essence of the method used each year in
Hungary for the past 11 years for seasonal vaccination.7 The
vaccine was produced as described previously.6 Briefly, the
virus strains were influenza A (H3N2), A (H1N1) and B
[for the 2006 ⁄ 07 season: Influenza A ⁄New Caledonia ⁄ 20 ⁄
99(H1N1), Influenza A ⁄Wisconsin ⁄ 67 ⁄ 2005 (H3N2), and
Influenza B ⁄Malaysia ⁄ 2506 ⁄ 2004. Strains for previous sea-
sons were as recommended each year by the WHO]. The
vaccine is a hens’ egg grown, formaldehyde-inactivated,
whole virus vaccine, which contains a minimum of 15 lg of
hemagglutinin (HA) ⁄dose ⁄ strain (as determined by single
radial immunodiffusion test), in one dose (0Æ5 ml) in
1Æ0 ml ampoules. The HA content was determined by single
radial immunodiffusion test, in 0Æ5 ml ampoules as
described previously.8 Purity was evaluated by endotoxin
content (determined by chromogenic endotoxin assay, uti-
lizing a modified limulus amoebocyte lysate and a synthetic
color-producing substrate to detect endotoxin presence),
which was measured to be present in concentrations less
than 0Æ05 IU ⁄dose, and the amount of ovalbumin deter-
mined by ELISA, which was less than 5 ng ⁄dose. Both val-
ues are much lower than the concentrations considered
acceptable by the European Pharmacopoeia (Ph. Eur.),
which are 100 IU ⁄human dose and 1000 ng ⁄human dose,
respectively.9 Aluminum phosphate (AlPO4) was used as
adjuvant, in the amount of 0Æ31 mg Al ⁄ ampoule and merti-
olate was added as preservative in the amount of 0Æ1mg ⁄ml,
meeting the requirements of Ph. Eur.9
The final composition of the vaccine for 0Æ5 ml is:
0Æ31 mg ⁄dose Al (as AlPO4), NaCl (1Æ66 mg), potassium
dihydrogen phosphate (0Æ31 mg), Disodium phosphate
dihydrate (0Æ19 mg), thiomersal (0Æ05 mg), KCl (0Æ04 mg)
to 0Æ5 ml sterile water.
The method fulfills all criteria for Good Manufacturing
Practice (GMP) and it has been validated by meeting the
requirements of the European Committee for Medicinal
Products for Human Use (CHMP) related to interpandem-
ic influenza vaccines each year since 1995, and by having
been administered in humans in Hungary in a total of
more than 15 million subjects since 1995.10,11
Subjects
Sixty healthy volunteers per age group (age of 18–60 years
and 60 years and older) were enrolled to receive annual vac-
cination each year. As recommended by the WHO, in 1999
and 2003 the seasonal influenza vaccines were produced
with the same strains as the previous year, and therefore, no
licensing studies were required, meaning that a total of 1080
subjects were studied. Negative urine or serum pregnancy
test was required for women of childbearing potential. Also,
in female subjects of childbearing potential, use of an
acceptable contraception method was required and the sub-
ject was not to become pregnant for the duration of the
study. Acceptable contraception included implants, injecta-
bles, combined oral contraceptives, intrauterine devices, sex-
ual abstinence, or a vasectomized partner. Exclusion criteria
included diagnosed immunodeficiency, history of Guillain–
Barre´ syndrome severe concomitant disease states (e.g.
uncontrolled diabetes, autoimmune disease, malignancy)
that may affect the immune reactivity of the individual, use
of immunosuppressive medication (corticosteroid nasal
sprays were permitted), medical or psychiatric condition
that precluded subject compliance with the study protocol,
receiving an inactivated vaccine 14 days prior to the study,
use of live attenuated vaccines within 60 days of study, use
of investigational agents within 30 days prior to the study,
receipt of blood products or immunoglobulins in the past
6 months, acute febrile illness 1 week before vaccination,
pregnancy or nursing, known allergies to any component of
the vaccine, including thiomersal, history of allergy to eggs
or egg products.
The sample size was chosen to exceed the requirements
of 50 patients per group by the European guidelines for
yearly influenza vaccine trials.11 All patients signed a written
informed consent. The study protocol was approved by the
National Institute of Pharmacy, Budapest, Hungary, and
the Central Ethics Committee for Clinical Pharmacology
of the Medical Research Council, Budapest, Hungary. The
study sponsor was the National Public Health and Medical
Officer Service, Budapest, Hungary, and Omninvest Ltd,
Budapest, Hungary. The funding source had no role in the
conduct of the study or the preparation of this report.
Laboratory tests
Serum antibody titers were measured by hemagglutination
inhibition (HI) following standard procedures.12,13
All serological tests were performed at a central labora-
tory (Department of Virology, National Center for Epide-
miology, Budapest, Hungary).
Immunogenicity assessment
Hemagglutination inhibition antibody titers were deter-
mined at baseline and on day 21 after vaccination. HI
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titers were used to calculate seroconversion rates, seropro-
tection rates, and increase in geometric mean titers
(GMT). Immunogenicity was assessed according to the
criteria of the European Agency for the Evaluation of
Medicinal Products (EMEA) and the European Centre for
Disease Protection and Control (ECDC) related to inter-
pandemic and pre-pandemic influenza vaccines.11,15 In
order to confirm protective immunogenicity in adult
patients, one of the following three requirements have to
be met: (i) seroprotection, i.e. achievement of an HI titer
of ‡1:40 in >70% of subjects; (ii) seroconversion, i.e.
a ‡4-fold increase in HI antibody titer, or reaching a titer
of ‡1:40, in >40% of subjects; and (iii) an increase in
GMT by >2Æ5-fold. For patients >60 years of age, the fol-
lowing criteria were used: (i) seroconversion, i.e. a ‡4-fold
increase in HI antibody titer, or reaching a titer of ‡1:40,
in >30% of subjects; (ii) seroprotection, i.e. achievement
of an HI titer of ‡1:40 in 60% of subjects; and (iii) an
increase in GMT by >2-fold.11,15 The above guidelines
have also been proposed in a draft guideline by the US
Food and Drug Administration (FDA), with the exception
of the GMT increase criterion.15 Efficacy was assessed by
comparing the rates of laboratory confirmed influenza
cases between the vaccinated and unvaccinated population
each season.
Procedures
Baseline evaluations included demographic data, medical
history and physical examination, recording pre-existing
conditions, concomitant medications, vital signs (blood
pressure, pulse rate). In case of female subjects of child-
bearing age, a pregnancy test was performed. Blood sam-
ples were taken from the cubital vein to test for specific
antibodies against the virus strains by HI. The purpose of
the day 0 serological examination was to test for the pres-
ence of such antibodies prior to treatment.
After a physical examination and blood collection,
0Æ5 ml of the vaccine was administered at one side into the
deltoid muscle by a deep intramuscular injection. The
injection was not repeated. On day 21, medical history and
the list of any medications used during the days since the
last visit were taken, physical examination was performed,
and blood samples were taken from the cubital vein to test
for specific antibodies against the virus strains by HI.
Statistical analysis
We assessed the occurrence of the following reactions in
the 3 days after vaccination in accordance with guidance
for interpandemic vaccines: injection site induration of
more than 5 cm for more than 3 days; injection site ecchy-
mosis; body temperature of more than 38Æ0C – i.e. oral
temperature of greater than 37Æ5C – for 24 hours or more;
malaise; and shivering.16
We gave HI titers below the limit of detection an arbi-
trary intermediate value of one in two. The geometric
mean of duplicate results for each specified time was used
for the calculation. Geometric mean titers of antibody and
their confidence intervals were computed by transforming
the results to a logarithmic scale, assuming asymptotic nor-
mality conditions were satisfied on the scale and converting
back to the original scale. The HI endpoints were the
GMT, as well as the variables recommended for interpan-
demic influenza vaccines: post-vaccination seropositivity
rate (% of subjects with titers ‡64, which is higher than
the titer of 1:40 required by the CHMP and FDA); the
post-to-pre-vaccination GMT ratio; and the proportion of
people seroconverting, meaning displaying an at least four-
fold titer increase post-vaccination and post-vaccination
titers of at least 1:64, which again, is higher than the
CHMP and FDA requirement of 1:40.11,14,15 We used Fish-
er’s exact test and the non-parametric Kruskal–Wallis test
as appropriate to test for differences between groups. A P
value of <0Æ05 was considered significant.
Results
Immunogenicity
Immunogenicity findings of adult and elderly subjects are
summarized in Tables 1 and 2 for the years of 1997, 1998,
2000, 2001, 2002, 2004, 2005, 2006 and 2007. As recom-
mended by the WHO, in 1999 and 2003 the seasonal influ-
enza vaccines were produced with the same strains as the
previous year. Therefore, no licensing studies were
required.
The pre- and post-vaccination HA antibody titers for
both age groups are shown in Figures 1 and 2 for each
virus strain in the season of 2007.
The vaccines met at least one independent CHMP crite-
rion for licensure for every influenza season. In adult sub-
jects, all three licensing criteria were met each year.
In elderly subjects, all three criteria were met each year,
with the exception of 1997, when seropositivity for influ-
enza A (H1N1) and influenza B were only close to the 60%
criterion (52 and 58%, respectively). Nonetheless, the crite-
ria for seroconversion and GMT increase were met each
year, including 1997, meaning that the vaccine fulfilled
CHMP licensing criteria for interpandemic influenza vac-
cines in every season. Thus, the requirement for licensure,
e.g. meeting at least one independent criterion, was fulfilled
each year.
Efficacy
The efficacy of the vaccine produced in Hungary 1962–
2007 was 25–92%, which is in line with the international
findings of efficacy.17,18 The lowest rate was found in 1978,
which is due to the fact that the epidemic was caused by
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the A ⁄USSR ⁄ 90 ⁄ 77(H1N1) strain. This subtype returned
unexpectedly, after 20 years, and, therefore, the vaccine
produced based on the yearly WHO recommendation did
not contain it. The efficacy rate was especially low, 3Æ3% in
the population younger than 20 years of age. However, a
41Æ7% efficacy rate was found in persons older than
20 years. This is likely explained by the fact that the popu-
lation over 20 years of age had been exposed to that strain
before, and, therefore, could have had some protection
against it, which was boosted with the vaccine by non-spe-
cific immunostimulation. The effects of repeated annual
vaccinations were not studied in the present work. How-
ever, we do have some data suggesting that repeated vacci-
nations enhance the immune response, or even cross
reactive immunity.19
Safety
Each year, in £1Æ67% of the participants, adverse reactions
in the form of local pain or erythema at the injection site
occurred within the first 48 hours; these reactions disap-
peared within 1 day. No other local reactions, such as
injection site induration, swelling, warmth, or ecchymosis,
were noted. No systemic reaction (fever, malaise, headache,
shivering) was detected. No serious adverse events were
observed in the study population. This is supported by the
yearly reaction reports from the Department of Viral Vac-
cine Control, National Center for Epidemiology, Budapest,
Hungary, which published 0–5 reactions ⁄ year, from more
than 1 million vaccinations yearly.20
Discussion
Influenza disease is an underestimated public health prob-
lem. Epidemics spread rapidly from country to country
and may affect as many as 500 million people all over the
world in each year. The disease, particularly influenza A
may kill the patients and the new influenza viruses which
appeared in 1957 (Asian influenza) and 1968 (Hong Kong)
are estimated to have caused at least 3 000 000 deaths in
the world.
Seasonal influenza continues to have a huge annual
impact in the United States, accounting for tens of millions
of illnesses, hundreds of thousands of excess hospitaliza-
tions, and tens of thousands of excess deaths. Vaccination
remains the mainstay for the prevention of influenza.21
Children, adults <65 years of age, and the elderly all receive
Table 1. Immunogenicity findings of the
trivalent seasonal influenza vaccine FluvalAB
in adult subjects (18–60 years)
Year Strain
Seropositivity
(CHMP
criterion: >70%)
Seroconversion
(CHMP
criterion: >40%)
GMT increase
(CHMP
criterion: >2Æ5)
CHMP
requirement
met
1997 A(H1N1)
A(H3N2)
B
84%
85%
75%
41%
46%
43%
3Æ0
3Æ4
3Æ3
Yes
1998 A(H1N1)
A(H3N2)
B
86%
82%
86%
56%
50%
68%
4Æ7
3Æ6
4Æ2
Yes
2000 A(H1N1)
A(H3N2)
B
84%
70%
72%
72%
56%
62%
3Æ5
3Æ3
3Æ0
Yes
2001 A(H1N1)
A(H3N2)
B
84%
84%
79%
47%
46%
49%
3Æ4
3Æ1
3Æ4
Yes
2002 A(H1N1)
A(H3N2)
B
88%
90%
80%
62%
66%
54%
3Æ3
3Æ9
3Æ9
Yes
2004 A(H1N1)
A(H3N2)
B
72%
76%
86%
46%
54%
48%
3Æ4
2Æ6
3Æ6
Yes
2005 A(H1N1)
A(H3N2)
B
84%
78%
80%
44%
42%
48%
3Æ1
3Æ0
3Æ2
Yes
2006 A(H1N1)
A(H3N2)
B
88%
82%
77%
43%
47%
45%
2Æ8
3Æ5
3Æ0
Yes
2007 A(H1N1)
A(H3N2)
B
76%
80%
76%
52%
52%
50%
5Æ4
4Æ0
3Æ9
Yes
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substantial health benefits from vaccination. In addition,
vaccination appears to be cost-effective, if not cost saving,
across the age spectrum.2,21
Here we present the essence of the production and the
results of the yearly licensing studies of an inactivated
whole virus seasonal influenza vaccine with an aluminum
phosphate adjuvant system, which has been used for vacci-
nation in Hungary for 11 years and over 15 million sub-
jects in humans. The same method has been used to
produce a vaccine against influenza A (H5N1), which dem-
onstrated safety and efficacy in humans.6 Experts suggest
that the adaptation of existing technologies for seasonal
Table 2. Immunogenicity findings of the
trivalent seasonal influenza vaccine FluvalAB
in elderly persons (>60 years)
Year Strain
Seropositivity
(CHMP
criterion: >60%)
Seroconversion
(CHMP
criterion: >30%)
GMT increase
(CHMP
criterion: >2)
CHMP
requirement
met
1997 A(H1N1)
A(H3N2)
B
52%
68%
58%
32%
38%
31%
2Æ9
2Æ8
3Æ1
Yes
1998 A(H1N1)
A(H3N2)
B
62%
70%
78%
36%
44%
58%
2Æ9
2Æ7
4Æ0
Yes
2000 A(H1N1)
A(H3N2)
B
68%
70%
74%
44%
52%
56%
2Æ6
2Æ8
2Æ8
Yes
2001 A(H1N1)
A(H3N2)
B
67%
69%
70%
40%
38%
41%
2Æ9
2Æ8
2Æ7
Yes
2002 A(H1N1)
A(H3N2)
B
72%
82%
88%
38%
36%
44%
3Æ1
3Æ2
3Æ9
Yes
2004 A(H1N1)
A(H3N2)
B
72%
70%
82%
38%
32%
38%
3Æ3
3Æ1
3Æ2
Yes
2005 A(H1N1)
A(H3N2)
B
72%
70%
82%
32%
36%
42%
2Æ4
2Æ7
3Æ5
Yes
2006 A(H1N1)
A(H3N2)
B
75%
78%
70%
37%
40%
35%
2Æ7
3Æ1
2Æ8
Yes
2007 A(H1N1)
A(H3N2)
B
68%
68%
68%
42%
50%
42%
3Æ0
3Æ1
2Æ9
Yes
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Figure 1. Reverse cumulative distribution curve for HI antibody titers to homologous H1N1, H3N2 and B vaccine strains 21 days after vaccination in
the age group 18–60 years.
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influenza vaccine production would be the most straight-
forward approach to produce pandemic vaccines, because
these technologies are commercially available and licensing
would be relatively simple.4,5,21 However, the trials pub-
lished so far on H5N1 vaccines have reported very low
immunogenicity or used different methods than used for
the production of seasonal vaccines.22–25 There has also
been pandemic experience with the above described
method during the 1968 pandemic in Hungary.17 In 1968,
the number of influenza cases in Hungary was lower than
in the preceding and subsequent years, which is possibly
explained by the fact that in 1968 the number of vaccina-
tions was several folds higher than in any other year of the
decade.26
Inactivated influenza vaccines were first licensed in 1941
and they have been produced in Hungary since 1961. The
original method was developed by Takatsy.27 The essence
of the method is based on biological purification and con-
centration, achieved by dialysis.
In Hungary, approximately 1Æ5 million doses of seasonal
influenza vaccines are produced each year with the indus-
trial adaptation of the method described in this study.
Besides the fact that influenza vaccine production in Hun-
gary is independent of the world wide suppliers of vaccines
and uses a different approach, the importance of the above
also lies in the finding that the same method can be
applied to produce a vaccine against an influenza A
(H5N1) virus, which is highly pathogenic and considered
to be the potential cause of the next influenza pandemic.6
We recently reported the first clinical trial with 146 patients
having received an inactivated whole virus H5N1 vaccine.
It was found that the vaccine produced essentially with the
above method was safe and immunogenic in humans
inducing seroconversion in 63Æ7% of the study subjects
without side effects other than injection site pain.6 More-
over, as opposed to other reports with H5N1 vaccines, it
was found to be immunogenic after only one injection.6,22–
25 Furthermore, we also tested the pre-pandemic H5N1
vaccine produced with the above method in children, and
confirmed its immunogenicity and safety.28 Therefore, the
vaccine has been officially offered to be part of the WHO
pre-pandemic vaccine stockpile.29
In Hungary, a ‘cold capacity’ has been developed, which,
using the virus strain supplied by the WHO, enables the
production of the first 500 000 doses of pandemic vaccine
in 8 weeks. In another 9 weeks, the production of the 4Æ5
million doses needed for a pandemic in Hungary can be
produced, using the above method.
There is some evidence that whole-virus vaccines are
more immunogenic than split or subunit vaccines, but this
needs substantiating by further studies. As far as seasonal
influenza vaccinations, the vaccine we studied provided
results compatible with non-adjuvanted split or subvirion
vaccines as they all meet CHMP licensing requirements. In
the case of pandemic influenza vaccines, non-adjuvanted
split and subvirion vaccines performed poorly in clinical
trials.22,23 We feel that developing an effective adjuvant sys-
tem is of importance, as H5 vaccines appear to be particu-
larly poor immunogens and there is evidence that an
adjuvant may be needed to boost their effect.30 We report
the use of a simple effective method of creating an alumi-
num phosphate-based adjuvant system complying with all
principles and detailed guidelines of CHMP on adjuvants
in vaccines for human use.31,32 We previously carried out
experiments with a different, aluminum hydroxide-based
adjuvant system, which we found much less effective and
0
0.2
0.4
0.6
0.8
1
1.2
N
eg
a
tiv
e
1:
32
1:
64
1:
12
8
1:
161:
8
1:
25
6
1:
32
1:
64
1:
12
8
1:
161:
8
1:
25
6
1:
32
1:
64
1:
12
8
1:
161:
8
1:
25
6
Influenza A H1N1
0
0.2
0.4
0.6
0.8
1
1.2
N
eg
at
ive
Influenza A H3N2  
0
0.2
0.4
0.6
0.8
1
1.2
Ne
ga
tiv
e
Influenza B
Before vaccination
After vaccination
Before vaccination
After vaccination
Before vaccination
After vaccination
Figure 2. Reverse cumulative distribution curve for HI antibody titers to homologous H1N1, H3N2 and B vaccine strains 21 days after vaccination in
the age group over 60 years.
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stable than the above described aluminum phosphate-based
gel system in laboratory and animal studies (Jankovics
et al., unpublished data). A potential explanation of this is
the observation that the pH of the aluminum hydroxide
system changes more after autoclaving compared with alu-
minum phosphate systems, and that the absorption of
influenza viruses to the adjuvant largely depends on the
pH. We are currently conducting a large clinical trial, in
which 3Æ5 and 6 lg of HA are used in seasonal flu vaccina-
tions, as opposed to the conventionally used 15 lg.
We consistently detected a very low rate of side effects
each year. In general, whole, inactivated virus vaccines are
thought to be more reactogenic than split virion or subunit
vaccines, but the few side effects seen with the present vac-
cine may be explained at least in part by the purity of the
vaccine. The endotoxin content of 0Æ05 IU ⁄dose and the
amount of ovalbumin of less than 5 ng ⁄dose in the present
vaccine are much smaller than the allowed amounts of
100 IU ⁄dose and 1000 ng ⁄human dose, respectively,
accepted by standards.9 The present vaccine has been
approved and used in children, and a similarly low-rate of
side effects has been observed.
In summary, we report a method of vaccine production
that is different from those used by worldwide manufactur-
ers and yearly licensing studies for seasonal influenza vac-
cines that demonstrate that the vaccine is safe and effective.
This method has successfully been used to produce a pre-
pandemic vaccine using a virus strain with pandemic
potential.
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